Skip to main content

Table 1 Clinicopathologic characteristics and distribution of FOXP3+ intratumoral lymphocytes (iTILs) in the study population

From: Prognostic significance of FOXP3+ tumor-infiltrating lymphocytes in breast cancer depends on estrogen receptor and human epidermal growth factor receptor-2 expression status and concurrent cytotoxic T-cell infiltration

Characteristics Number of patients FOXP3+ iTILs (≥2)
  (%) Prevalence % Pvalue
Age at diagnosis (year)    <0.001
<40 294 (7.4) 41.6 (106/255)  
40-49 844 (21.1) 38.5 (264/685)  
50-65 1,425 (35.7) 29.5 (350/1186)  
>65 1,429 (35.8) 27.0 (311/1150)  
Grade    <0.001
1 (well differentiated) 209 (5.2) 16.3 (25/153)  
2 (moderately well or partially differentiated) 1,563 (39.2) 23.7 (305/1288)  
3 (poorly differentiated) 2,040 (51.1) 38.9 (661/1699)  
Unknown 180 (4.5)   
Tumor size (cm)    0.201
≤2 2,078 (52.1) 30.2 (512/1697)  
>2-5 1,667 (41.8) 33.1 (461/1394)  
> 5 221 (5.5) 29.8 (50/168)  
Unknown 26 (0.6)   
Nodal status    0.003
Negative 2,265 (56.7) 29.4 (545/1856)  
Positive 1,719 (43.1) 34.2 (484/1414)  
Unknown 8 (0.2)   
Lymphovascular invasion (LVI)    0.218
Negative 2,106 (52.8) 30.3 (522/1720)  
Positive 1,710 (42.8) 32.4 (461/1423)  
Unknown 176 (4.4)   
AJCC stage    0.003
I 1,393 (34.9) 27.7 (314/1132)  
II 2,255 (56.5) 33.7 (630/1872)  
III 317 (7.9) 32.2 (82/255)  
Unknown/missing 27 (0.7)   
Adjuvant systemic therapy (AST)*    <0.001
No AST 1,676 (42.0) 29.0 (402/1386)  
Tamoxifen only 1,276 (32.0) 27.7 (287/1037)  
Chemotherapy only 727 (18.2) 40.6 (245/603)  
Tamoxifen + chemotherapy 297 (7.4) 38.8 (92/237)  
Other 16 (0.4) 35.7 (5/14)  
ER    <0.001
Negative 1,200 (30.1) 42.7 (388/909)  
Positive (≥1% nuclei stained) 2,761 (69.1) 27.2 (641/2354)  
Uninterpretable/missing 31 (0.8)   
HER2    <0.001
Negative 3,316 (83.1) 29.9 (830/2779)  
Positive 498 (12.5) 42.4 (184/434)  
Uninterpretable/missing 178 (4.4)   
Subtype    <0.001
Luminal A 1,518 (38.0) 20.8 (275/1325)  
Luminal B 829 (20.8) 36.8 (276/749)  
Luminal/HER2 224 (5.6) 39.5 (79/200)  
Luminal not further assigned 244 (6.1) 19.5 (29/149)  
HER2+/ER– 250 (6.3) 45.9 (102/222)  
TNP 630 (15.8) 42.2 (226/535)  
Core basal 330 (8.3) 54.0 (163/302)  
5NP 162 (4.1) 36.5 (50/137)  
TNP not assignable 138 (3.4) 39.5 (34/86)  
Unassignable 297 (7.4) 21.5 (23/107)  
CD8+ iTIL    <0.001
0 2,299 (57.6) 19.6 (410/2094)  
≥1 1,104 (27.6) 56.6 (591/1044)  
Uninterpretable/missing 589 (14.8)   
Total 3,992 (100) 31.5 (1031/3277)  
  1. *Chemotherapy was methotrexate, cyclophosphamide, 5-fluorouracil (CMF), doxorubicin and cyclophosphamide (AC) or doxorubicin, cyclophosphamide, 5-fluorouracil (FAC). Trastuzumab was not available to these patients. 5NP, five-marker negative phenotype; AJCC, American Joint Committee on Cancer; ER, estrogen receptor; HER2, human epidermal growth factor receptor-2; iTILs, intratumoral tumor-infiltrating lymphocytes; TNP, triple-negative phenotype.